Company profile: BetterLife Pharma
1.1 - Company Overview
Company description
- Provider of nutraceuticals and pharmaceuticals, engaged in production and commercialization, with product candidates including BETR-001, a non-hallucinogenic LSD derivative for psychiatric and neurological disorders; BETR-002, a hydrohonokiol derivative for benzodiazepine dependency, anxiety, and neurodegenerative disorders (oral capsule); and a viral infection candidate, including COVID-19, via subsidiary MedMelior.
Products and services
- BETR-002: A hydrohonokiol derivative intended to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders, delivered as oral capsules
- Capsule-based formulation.
- BETR-001: A non-hallucinogenic LSD derivative targeting psychiatric and neurological disorders without causing hallucinations
- Custom-engineered to deliver therapeutic activity absent hallucinatory adverse effects.
- Drug candidate for viral infections (MedMelior): A drug candidate developed through subsidiary MedMelior for treating viral infections, including COVID-19
- Subsidiary-developed for antiviral therapeutic development.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BetterLife Pharma
Santhera Pharmaceuticals
HQ: Switzerland
Website
- Description: Provider of pharmaceutical products for mitochondrial and neuromuscular diseases; develops and markets therapies for areas of high unmet medical need, including many orphan and niche indications with no current therapy, such as Vamorolone for Duchenne muscular dystrophy targeting inflammation and dystrophic cardiomyopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Santhera Pharmaceuticals company profile →
XW Pharma
HQ: United States
Website
- Description: Provider of neuroscience biotech R&D focused on sleep, neuropsychiatric, and neglected CNS illnesses. Pipeline includes XWL-008, a proprietary narcolepsy compound preparing for late-stage phase 3; XW10172, a patented once-nightly conjugate of the GABAB agonist oxybate for sleep disorders in patients with neurodegenerative diseases; and XW10508, an oral, once-daily NMDA antagonist/AMPA activator for treatment-resistant depression and chronic pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XW Pharma company profile →
Synchron
HQ: United States
Website
- Description: Provider of neuromodulation solutions in bioelectronics medicine for previously-untreatable nervous system conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synchron company profile →
Jupiter Neurosciences
HQ: United States
Website
- Description: Provider of biotechnology therapies targeting Alzheimer's and rare neurological disorders, including JOTROL, an oral micellar resveratrol formulation designed to deliver therapeutic doses without side effects. The company pursues a pipeline strategy using a Phase I study to enable trials for three rare diseases and mild cognitive impairment to proceed directly to Phase II.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jupiter Neurosciences company profile →
ArmaGen
HQ: United States
Website
- Description: Provider of therapies and siRNA delivery technologies that penetrate the blood-brain barrier to treat neurological complications of diseases, including lysosomal storage disorders (LSDs), Alzheimer's and Parkinson's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArmaGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BetterLife Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BetterLife Pharma
2.2 - Growth funds investing in similar companies to BetterLife Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BetterLife Pharma
4.2 - Public trading comparable groups for BetterLife Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →